연구동향 분석

Left Atrial Appendages Occlusion: Current Status and Prospective

Sharan Prakash Sharma Dhanunjaya Lakkireddy 2018년

논문상세정보
인용/피인용

' Left Atrial Appendages Occlusion: Current Status and Prospective' 의 참고문헌

  • aMAZE Study: LAA ligation adjunctive to PVI for persistent or longstanding persistent atrial fibrillation (aMAZE) [Internet]
  • Watchman LAA closure technology -P130013 [Internet]
  • Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA) : a randomised controlled trial
    Mant J [2007]
  • Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
    Klein AL [2001]
  • Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device
    Enomoto Y [2017]
  • Update on atrial fibrillation: part I
    Savelieva I [2008]
  • Two-year clinical outcome from the Iberian registry patients after left atrial appendage closure
  • Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet
    Kleinecke C [2017]
  • Time to cost-effectiveness following stroke reduction strategies in AF: warfarin versus NOACs versus LAA closure
    Reddy VY [2015]
  • Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis
    Tsai YC [2015]
  • Side-by-side comparison of LAA occlusion performance with the Amplatzer cardiac plug and Amplatzer Amulet
    Abualsaud A [2016]
  • Short and long-term outcomes of percutaneous left atrial appendage suture ligation: results from a US multicenter evaluation
  • Sequential percutaneous LAA ligation and pulmonary vein isolation in patients with persistent AF: initial results of a feasibility study
    Badhwar N [2015]
  • Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence
    Miyasaka Y [2006]
  • Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the continued access registry
    Reddy VY [2011]
  • Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation
    Alli O [2013]
  • Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial
  • Prevalence of diagnosed atrial fibrillation in adults : national implications for rhythm management and stroke prevention : the AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study
    Go AS [2001]
  • Predictors of early (1-week) outcomes following left atrial appendage closure with Amplatzer devices
    Koskinas KC [2016]
  • Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation
    Reddy VY [2017]
  • Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience
    Bartus K [2013]
  • Percutaneous left atrial appendage occlusion using different technologies in the United Kingdom: a multicenter registry
    Betts TR [2017]
  • Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug
    Santoro G [2016]
  • Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy
    Urena M [2013]
  • Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial
    Holmes DR [2009]
  • New technical and anticoagulation aspects for left atrial appendage closure using the WATCHMAN(R) device in patients not taking warfarin
    Meincke F [2013]
  • Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Hart RG [2007]
  • Long-term outcomes following percutaneous left atrial appendage closure in patients with atrial fibrillation and contraindications to anticoagulation
    Regueiro A [2018]
  • Long-term event reduction after left atrial appendage closure. Results of the Iberian Registry II
  • Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study
  • Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation
    Berti S [2016]
  • Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug
    Tzikas A [2016]
  • Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation
    Onalan O [2007]
  • Left atrial appendage closure: initial experience with the ultraseal device
    Regueiro A [2017]
  • Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology)
    Reddy VY [2013]
  • Left atrial appendage closure vs. novel anticoagulation agents in atrial fibrillation (PRAGUE-17) [Internet]
  • Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation : a patient-level meta-analysis
  • Left atrial appendage closure and systemic homeostasis: the LAA HOMEOSTASIS study
  • Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation
    Sick PB [2007]
  • Initial experience with novel oral anticoagulants during the first 45 days after left atrial appendage closure with the Watchman device
    Bosche LI [2015]
  • Implant success and safety of left atrial appendage occlusion in end stage renal disease patients: peri-procedural outcomes from an Italian dialysis population
    Genovesi S [2018]
  • Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry
    Boersma LV [2016]
  • Impact of left atrial appendage exclusion using an epicardial ligation system (LARIAT) on atrial fibrillation burden in patients with cardiac implantable electronic devices
    Afzal MR [2015]
  • Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation
    Lee OH [2018]
  • Exclusion of the left atrial appendage with a novel device: early results of a multicenter trial
    Ailawadi G [2011]
  • Epicardial left atrial appendage clip occlusion also provides the electrical isolation of the left atrial appendage
    Starck CT [2012]
  • Endocardial (Watchman) vs epicardial (Lariat) left atrial appendage exclusion devices: understanding the differences in the location and type of leaks and their clinical implications
  • Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium
    Price MJ [2014]
  • Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation
    Gloekler S [2015]
  • Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation
    Fauchier L [2018]
  • Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin
    Reddy VY [2016]
  • Coherex WAVECREST I left atrial appendage occlusion study [Internet]
  • Brain natriuretic peptide levels variation after left atrial appendage occlusion
  • Atrial and brain natriuretic peptide secretion after percutaneous closure of the left atrial appendage with the Watchman device
    Majunke N [2015]
  • Assessment of the WATCHMANTM Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) [Internet]
  • Assessment of device-related thrombus and associated clinical outcomes with the Watchman left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF trial)
    Main ML [2016]
  • Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
  • Amplatzer left atrial appendage occlusion: single center 10-year experience
  • AMPLATZERTM AmuletTM LAA Occluder trial (Amulet IDE) [Internet]
  • 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials
    Reddy VY [2017]
  • 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
    Kirchhof P [2016]
  • 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society
    January CT [2014]